Skip to main content
OpenTrials
Completed

NCT Number: NCT00221546

Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

About this study

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Delta F 508 homozygote
  • Stable clinical situation

Exclusion criteria

-

Treatment and study plan

Giving DHA-rich supplement

Drug

Giving DHA-rich supplement to patients.

Primary outcomes

  1. Clinical evolution: weight, height, pulmonary function and infection frequency before the study start and during the 2 years of the study

    Time frame: before the study start and during the 2 years of the study

Secondary outcomes

  1. Evolution of the fatty acid profile

    Time frame: during the 2 years of the study

  2. Oxidative stress status

    Time frame: during the 2 years of the study

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • Belgian Society against Cystic Fibrosis

Registry information

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 22, 2005
Registry last updated
Sep 28, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.